OMALIZUMAB (Xolair) prior authorization at Point32Health
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Point32Health requires Anti-IgE prior-authorization documentation for OMALIZUMAB (Xolair): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Point32Health reviews OMALIZUMAB (Xolair) prior authorizations against its medical policy for Anti-IgE. Point32Health-specific context: Formed by 2021 merger of Tufts Health Plan and Harvard Pilgrim Health Care; ~2M members across New England. Brands operate separately (Harvard Pilgrim, Tufts Health Plan). MA DOI primary regulator; MA OPP external review applies in Massachusetts.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Anti-IgE
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Point32Health's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Harvard Pilgrim vs Tufts Health Plan operational differences (pre-merger legacy)
- MA mandated benefit disputes
- Specialty drug PA
- Behavioral health prior auth
OMALIZUMAB (Xolair)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- IgE level thresholds (30-1500 IU/mL) for asthma indication
- Indication restriction (asthma vs CIU vs nasal polyps vs food allergy)
- Step therapy requiring trial of inhaled corticosteroid + LABA first
Brand: Xolair. Anti-IgE monoclonal antibody. FDA-approved for moderate-to-severe persistent allergic asthma, chronic idiopathic urticaria, nasal polyps, and food allergy IgE-mediated (February 2024 — first FDA-approved drug to reduce allergic reactions to multiple foods).
Manufacturer patient-assistance program: Genentech Access Solutions — relevant when a Point32Health denial sticks and the patient needs bridge access while appealing.
How Point32Health approaches Biologic drugs (mAbs and biosimilars) PAs
For OMALIZUMAB (XOLAIR), check whether the current Point32Health Biologic drugs (mAbs and biosimilars) policy cites specialty drug pa. Pharmacy-benefit review for OMALIZUMAB (XOLAIR) at Point32Health is routed through Express Scripts (Harvard Pilgrim and Tufts Health Plan brands). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Point32Health; if denied, use the filing date and route printed on that denial notice. Point32Health's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Point32Health is domiciled in MA, so unresolved appeals escalate to the MA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.point32health.org/providers) with the same packet plus an applicable, current clinical source supporting OMALIZUMAB (Xolair)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Point32Health denial on DenialHelp.
Contact Point32Health
- Provider portal: https://www.point32health.org/providers
Frequently asked questions
What documentation does Point32Health need for OMALIZUMAB (Xolair) prior auth?
Point32Health's typical PA packet for OMALIZUMAB (Xolair): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Anti-IgE, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Point32Health?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for OMALIZUMAB (Xolair) at Point32Health?
Preparation scenarios to check against the current notice and policy include: Harvard Pilgrim vs Tufts Health Plan operational differences (pre-merger legacy); MA mandated benefit disputes; Specialty drug PA. These are not measured frequency claims. For OMALIZUMAB (Xolair), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
What prior failures does Point32Health typically require before approving OMALIZUMAB (XOLAIR)?
Point32Health's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For OMALIZUMAB (XOLAIR), attach the specific disease-activity instrument Point32Health accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Express Scripts (Harvard Pilgrim and Tufts Health Plan brands). External-review escalation for Point32Health fully-insured policies sits with the MA insurance department.
How do I prep for a peer-to-peer with Point32Health on OMALIZUMAB (Xolair)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the OMALIZUMAB (Xolair) PA packet
Open ApprovalHelp — generate a OMALIZUMAB (Xolair) prior-auth packet tailored to Point32Health's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com